Post on 10-Jul-2020
Life Sciences SectorOpportunities for Investment, Talent and Enterprise
British Columbia Technology Sector Profile
= 20 Employees
= 2 Companies
29 Companies 443 Employees
123 Companies 1,849 Employees
18 Companies 272 Employees
9 Companies 136 Employees
Vancouver Island16% Lower Mainland
69%
Interior10%
Northern B.C.5%
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
= 20 Employees
= 2 Companies
29 Companies 443 Employees
123 Companies 1,849 Employees
18 Companies 272 Employees
9 Companies 136 Employees
Vancouver Island16% Lower Mainland
69%
Interior10%
Northern B.C.5%
i�
British Columbia Technology Sector Profile
Message from the MinisterBritishColumbiaishometoathri�ingbiotechnologyindustry;infact,wearethefastestgrowingbiotechcentreinCanada,makingusthe7thlargestinNorthAmerica.
Weha�ebuiltourindustrybyin�estinginworld-classresearchinstitutionsandbyde�elopingworld-classtalent.O�erthepastfewyearsweha�ein�estedo�er$�.5billioninourscienceinfrastructure.Mostrecently,weha�epro�ided$�72millionforanewLifeSciencesCentreattheUni�ersityofBritishColumbia,and$25millionfortheCentreforDrugResearchandDe�elopmenttohelpresearcherscollaborate,refinetheirdisco�eriesandde�elopthemforcommercialuse.
Inadditiontoourcommitmenttode�elopinginfrastructureandtalent,BritishColumbiaoffersoneofthemostprogressi�eandcost-effecti�eR&Den�ironmentsinNorthAmerica,offeringspecifictaxad�antagestolifesciencecompanies.Thisinturnhasgi�enusoneofthebestreturnsonin�estmentperresearchdollarinNorthAmerica.
WitheasyaccesstomarketsinAsia,EuropeandtheU.S.andanunparalleledqualityoflife,B.C.istrulyabeautifulplaceforlifesciencebusinessestothri�e.
ColinHansenMinisterofEconomicDe�elopment
beautifulplaceforlifesciencebusinessestothri�e.
ColinHansen
�
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
1 Executive Summary
2 Sector Description and Overview in British Columbia
SectorHighlights
ResearchInfrastructureandPublicIn�estment
3 Profile of 20 Largest B.C. Companies
4 Centres for Research and Innovation
5 Skilled Workforce
6 Finance and Capitalization
FiscalIncenti�es
ResearchandDe�elopmentIn�estmentTaxCredits
InternationalFinancialActi�ityAct
SmallBusinessVentureCapitalAct
EmployeeIn�estmentAct
SocialSer�iceTaxAct
7 Value Chain / Ecosystem
Endnotes
1
2
3
4
6
12
14
24
24
25
26
27
28
28
30
36
Table of Contents
�
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
TheLifeSciencessectorinBritishColumbiaincludesorganizationsacti�eintheareasofbiopharmaceuticals,medicalde�ices,bio-productsandbioinformatics,amongstothers.iThesectorisdi�erseandinadditiontotheseareasitalsoincludesacti�ityinareassuchas:nanotechnology,agriculture,marine,en�ironmentalandforestry.Thisprofilefocusesonbiopharmaceuticals,whichisthelargestsub-sectorandhasthelargestconcentrationofpublicandpri�atein�estmentinresearch,companyformationandcommercialsuccess.Wherea�ailable,informationonotherareasofbiotechnologyacti�itysuchasmedicalde�iceshasbeenincluded.
InBritishColumbia,biopharmaceuticalsarethemostreadilyquantifiablecomponentofLifeSciences.Thebiopharmaceuticalssectorconsistsofupof9�companieswith2,200employees.Annualre�enuesforthebiopharmaceuticalindustryareapproximately$779millionaccordingtoa2005StatisticsCanadareport.
Incontrast,themedicalde�iceandbioproductssub-sectorsaresmaller.TheBCMedicalDe�iceTechnologiesAssociation(BCMedTech)reports63membercompaniesdirectlyin�ol�edwithde�icecreationwhiletheBCBioProductsAssociationreports25companies.
Life SciencesNumber of Companies �79(est.)
Number of Employees 2,700(est.)
Annual Revenue ($M) $800million+(est.)
3
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise 2
Sector HighlightsB.C.’sbiopharmaceuticalsectorisanchoredbythreeoftheworld’sfirstprofitablebiopharmaceuticalcompanies:QLT,AngiotechandAspre�a.WorldwidesalesforQLT’sleadproductVisudyne®in2004wereUS$448million,withsalesoftheirsecondcommercialproductEligard®totalingUS$84million.Visudyne®isoneofthemostsuccessfulophthalmologyproductse�er.
Angiotech’sleadproductisthepaclitaxel-elutingcoronarystent,TAXUS®whichhasnowbeenimplantedino�eramillionpatientsworldwidewith2004salestotalingUS$2.�45billion.
ThefollowingB.C.companiesarejustafewofthosepoisedtoachie�esignificantcommercialsuccess.
CardiomePharmaCorp.:RSD�235nowknownasVernakalantiscurrentlyinPhaseIIIClinicalTrialsforatrialfibrillationandhasanestimatedmarketofo�er$2billion.
Aspre�aPharmaceuticals:CellCeptcurrentlyinPhaseIIIclinicaltrialsforlupusnephritis.
Anormed,Inc.,aB.C.-basedbiotechnologycompany,wasrecentlyacquiredforapproximately$584millionbyGenzymeCorporation.Anormedwasinlate-stagePhaseIIIClinicalTrialswithMozobil,acancertreatmentdrugwhichisexpectedtobelaunchedintheU.S.in2008,subjecttosuccessfulcompletionofitsclinicaltrialsandregulatoryappro�al.
•
•
•
•
•
•
Areas of Life Sciences Specialty/Sub-sectorsBiopharmaceuticals
MedicalDe�ices
Bioproducts
Bioinformatics
Otherareasincluding:nanotechnology,agriculture,forestry,marine,andfood.
•
•
•
•
•
4
British Columbia Technology Sector Profile
ScientistsfromtheBCCancerAgency’sGenomeScienceCentresuccessfullysequencedtheSARS�irusin2003andtheInfluenzaA�irus(knownas“A�ianFlu”)in2004.
UBChasgenerated�20spin-offcompanies,ofwhich7�arestillacti�eandpro�ideemploymentforapproximately2,000people.Halfofthesecompaniesareinthelifesciencessector--UBCspin-offsha�ebeenhugelyinfluentialinde�elopingB.C.’sbiotechindustry.ii
SFUhasgenerated70spin-offcompanies,ofwhich45arestillacti�e.Twenty-fourpercentofthetotalspin-offcompaniesareusingtechnologiesde�elopedineitherthelifesciencesorbiomedicalengineeringareas.
B.C.isthe7thlargestbiotechnologycenterinNorthAmerica.CaliforniaisrankedaheadofB.C.withthemostcompaniesfollowedbyMassachusetts,Ontario,Quebec,NorthCarolinaandMaryland.
TheMilkenInstitute’s2006Uni�ersityTechnologyTransferandCommercializationIndexliststheUni�ersityofBritishColumbiaasthehighest-rankingCanadianinstitution,andeightho�erallinNorthAmericabehindfirstplacedMIT,theUni�ersityofCaliforniasystem(2nd),Caltech(3rd),Stanford(4th)andFlorida(5th).
BritishColumbia’spublicandpri�atebiotechfinancingfromallsourceswas$338millionU.S.in2005,representingthelargestpercentageoftotalfinancingintheCanadianindustryat33percent.Morethan69percentoftotalfundingwasfrompublicfinancingsources.
•
•
•
•
•
•
InMay2005,BCCancerAgencyspin-off,CelatorTechnologiesannouncedaUS$40millionpri�atefinancingdealtode�eloptechnologytocarryChemotherapeuticagentstodiseasesites.
Aspre�aPharmaceuticalsraised$��3minitsinitialpublicoffering,makingitthelargestIPOintheCanadianbiopharmaceuticalhistory.
Research Infrastructure and Public Investment:B.C.ishometotheMichaelSmithFoundationforHealthResearch,ago�ernmentsupportedfundingagencyforhealthresearch.Namedforthewinnerofthe�993NobelPrizeinChemistry,MichaelSmith,conductedgroundbreakingworkinDNAsequencingandgeneticengineering.Atpresent,theFoundationhasawardedfundingto�50healthresearchersand472healthresearchtraineesthroughoutB.C.’suni�ersitiesandteachinghospitalsatanin�estmentofalmost$90million.Inaddition,upto$24millionhasbeenin�estedinhealthresearchinfrastructurethroughoutthepro�ince.
TheBCCentreforDiseaseControl(BCCDC)isacomponentofthePro�incialHealthSer�icesAuthoritythatpro�idesintegrationbetweenthedeli�eryofpublichealthprogramswhilealsoattractingthebestscientistsandcliniciansforresearch.TheBCCDCincludesastate-of-the-artcontainmentle�el3facilityandmolecularlaboratorydiagnosticcapabilities,aswellascentralizedinformationmanagementsystems
RecentdatafromtheCanadianInstitutesofHealth(CIHR)pointstoanincreaseof��0percentinfundingtowardsB.C.healthresearchfromfederalsources–thelargestincreaseanywhereinCanada.
•
•
•
•
•
2
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
5
The$95million,23�,000sq.ft.BCCancerResearchCentrewascompletedinthefallof2004.Thefacilityhasthecapacitytohouseupto600scientificandmedicalpersonnel,andwillbringBCCancerAgencyresearchscientiststogetherinonelocation.Afurther�25,000sq.ft.dedicatedtofutureresearchisplannedforPhase2.
GenomeBritishColumbiaisin�estingo�er$278millionin28large-scaleresearchprojectsandfourtechnologyplatforms.Amongthoseprojectsarethefollowing:ApplicationofPharmacogenomicsforRationalChemotherapyofLungCancer,BetterBiomarkersofAcuteandChronicAllograftRejection,De�elopmentandValidationofComparati�eGenomicHybridizationArraysforClinicalUseinCancer,DissectingGeneExpressionNetworksinMammalianOrganogenesis,EfficientIdentificationandCloningofSingleGeneDeletionsintheNematodeCaenorhabditiselegansandFunctionalGenomicsforEmergingInfectiousDiseases(PREPARE)Project.
CenterforDrugResearchandDe�elopmentrecei�ed$25millionfromtheGo�ernmentofBritishColumbiain2007.CDRDbringstogetherresearchers,institutions,industryandfinancingtohelpbringad�ancesanddisco�eriestomarket.
•
•
•
6
British Columbia Technology Sector Profile
Thefollowingtableprofilesthetwentylargestcompaniesinthebiopharmaceuticalandmedicalde�icesub-sectorsinB.C.Therankingsarebasedprimarilyonre�enuesandsecondarily,employmentiii.ThislistincludescompaniesthatareheadquarteredinB.C.,aswellasthosewithlocationsinB.C.
ManytechnologycompaniesthroughoutB.C.arepri�atelyheld;therefore,informationoncompanyre�enuesandemploymentisoftennota�ailable.Followingthelistoftwentycompaniesisatablewiththenamesofse�eralpri�ately-heldcompaniesacknowledgedbytheirindustryasbeingtechnologyleaders.
Profile of 20 Largest B.C. Companies
3
7
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise 3Rank Company Revenue
(Most recently reported annual. CAN $M unless otherwise specified)
Employment Specialty Description
1 QLT Inc. www.qltinc.com
$280.9 B.C.: 210
Global: 240
Biopharmaceuticals; eye diseases, dermatological and urological conditions
QLT is engaged in the discovery, development and commercialization of therapies in the fields of opthamology and dermatology.
2 Angiotech Pharmaceuticals Inc. www.angiotech.com/
$231.8 B.C.: 73
Global: 1500
Drug-device combinations; developer of coronary stent system TAXUS.
Best known for its TAXUS Coronary Stent System, Angiotech is a specialty pharmaceutical company focused on developing and commercializing technologies that improve the performance of medical devices and the outcomes of surgical procedures.
3 Medical Imaging Group, a business unit of McKesson Provider Technologies www.mckesson.com
$214.0 B.C.: 500
Global: 639
Digital image management for hospitals and clinics: Horizon Radiology™ and Horizon Cardiology™
In 1988 was the first company to develop an electronic picture archiving and communications system (PACS) using personal computer/client server technology for ultrasound images.
4 Aspreva Pharmaceuticals www.aspreva.com
$88.7 B.C.: 63
Global: 103
Pharmaceuticals; develops and commercialized existing drug candidates for new applications
Aspreva is focused on identifying, developing and commercializing existing approved drugs and drug candidates for new indications.
5 Dragon Pharmaceuticals www.dragonpharma.com
$65.3 B.C.: n/k
Global: n/k
Generic pharmaceuticals; develops and markets therapeutic human protein drugs; markets and sells drugs in China
Three key divisions: biopharmaceutical, chemicals and bulk pharmaceuticals.
6 Forbes Medi-Tech www.forbesmedi.com/
$21.0 B.C.: 35
Global: 35
Cardiovascular disease Flagship product is Reducol for lowering Cholesterol.
8
British Columbia Technology Sector Profile
7 StemCell Technologies www.stemcell.com/
$19.4 B.C.: 145
Global: 161
Specialized media and cell separation products
StemCell Technologies is a world leader in the development of products for stem cell biology and has worked to standardize the field through the Global Proficiency Testing Program. Combining StemCell Technologies’ industry standard reagents and a team of experts in hematopoiesis and stem cell biology, StemCell Technologies assists organizations in drug development, agrochemical production, environmental toxicant testing and research.
8 Cardiome Inc. www.cardiome.com/
$16.1 B.C.: 74
Global: 74
Drug research and development focused on cardiovascular disease
Cardiome engages in drug research and development for the cardiovascular disease therapeutic market. Cardiome has two product candidates for treatment of arterial arrhythmia; Vernakalant (iv) (intravenous dosing) and Vernakalant (oral) (oral dosing). Vernakalant (iv) has completed Phase III trials.
9 Tekmira Pharmaceuticals Corp. www.inexpharm.com/
$15.4 B.C.: 30
Global: 30
Biopharmaceuticals for the treatment of cancer
Tekmira Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer
10 International Newtech Development Inc. (IND Diagnostic, Inc.) www.ind.ca/
$13.1 B.C.: n/k
Global: 120
In-vitro diagnostic (IVD) test systems.
Biotechnology company specializing in research, development and manufacturing of advanced in-vitro diagnostic (IVD) test systems.
11 VSM Medtech Ltd. www.vsmmedtech.com/
$11.2 B.C.: 148
Global: 148
Neurological disorders and cardiovascular diseases.
Manufactures a family of non-invasive vital sign monitors.
12 Xenon Pharmaceuticals Inc. www.xenon-pharma.com
Est. $6.6 B.C.: 69
Global: 69
Genetics-based drug development.
Xenon Pharmaceuticals is a clinical genetics-based drug discovery and development company engaged in developing small molecule therapeutics based on the genetic causes of select metabolic, neurological and cardiovascular diseases.
Rank Company Revenue Employment Specialty Description
3
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
9
13 Nventa Biopharmaceutical Corporation (formerly StressGen Biopharmaceuticalnologies Corp.) www.nventacorp.com
$5.7 B.C.: n/k
Global: 27
Vaccines for the treatment of infectious diseases and cancers.
Nventa is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV).
14 Response Biomedical www.responsebio.com
$3.5 B.C.: 76
Global: 79
Medical point of care (POC) and on-site environmental testing.
Response Biomedical Corporation develops, manufactures and markets rapid on-site diagnostic
tests for use with its RAMP System for clinical and environmental applications.
15 Chromos Molecular Systems Inc. www.chromos.com
$3.2 B.C.: 26
Global: 27
Therapeutic products for the treatment of debilitating diseases
Chromos is a biopharmaceutical company with two drug development programs focused on inflammatory diseases and thrombotic disorders
16 Xillix Technologies Corp. www.xillix.com
$3.0 B.C.: 65
Global: 71
Medical imaging technologies for cancer detection
Founded in 1991, based on technology developed at the BC Cancer Agency.
Xillix has an extensive auto-fluorescence and multi-modal imaging portfolio of 31 issued patents and multiple pending applications in the United States, Japan and Europe.
(Navadeq Technologies Inc. has entered into an agreement to purchase certain assets of Xillix (April 2007).
17 Pyng Medical Corp. www.pyng.com
$2.8 B.C.: n/k
Global: n/k
Manufacturing and sales of emergency medical products
Pyng is a biomedical joint venture partnership created to develop and commercialize emergency medical devices.
Pyng manufactures F.A.S.T.1, an intraosseous device for military and civilian emergency applications.
Rank Company Revenue Employment Specialty Description
�0
British Columbia Technology Sector Profile
18 Migenix Inc. www.migenix.com
$3.0 B.C.: 23
Global: 28
Drugs to treat or prevent infectious, degenerative and metabolic diseases
MIGENIX develops and commercializes drugs for the prevention and treatment of major medical diseases and certain conditions with unmet medical need. It is focused on advancing its pipeline of product candidates in the areas of infectious and degenerative diseases.
19 Wex Pharmaceuticals Inc. www.wextech.ca
$0.6 B.C.: 90
Global: 90
Drug products for the management of pain
Wex is focused on the development and commercialization of innovative drug products, primarily for pain management. WEX’s lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company’s development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.
20 AnorMed Inc. www.genzyme.com
$0.3 B.C.: 137
Global: 137
Hematology, human immunodeficiency virus (HIV) and oncology
AnorMED is a biopharmaceutical company that focuses on discovery, development, and commercialization of therapeutics in hematology, oncology, and HIV. Its leading product candidate is MOZOBIL, currently in Phase III studies in cancer patients undergoing stem cell transplants.
In November 2006, Genzyme Corporation, based in Cambridge, MA, acquired AnorMED for US$584 million and is conducting two separate Phase III trials for MOZOBIL.
3Rank Company Revenue Employment Specialty Description
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
��
Privately held Life Sciences companies(namescompiledbyPwCinconjunctionwithindustryassociationsandotherrelatedsources)
Company Area of Technology Website
Oncogenex™ Technologies, Inc. De�elopmentandcommercializationofcancertherapies www.oncogenex.ca
Neuromed Pharmaceuticals, Inc. De�elopingthenextgenerationchronicpaindrugs www.neuromed.com
Inflazyme Pharmaceuticals, Ltd. De�elopingmedicalbreakthroughstotransformtheli�esofpatientswithrespiratoryandinflammatorydiseases
www.inflazyme.com
Celator Pharmaceuticals, Inc. De�elopingnewandmoreeffecti�etherapiestotreatcancer www.celatorpharma.com
Ondine Biopharma Corporation De�elopinganinno�ati�elaser-acti�atedapproachtobroad-spectrumdisinfection
http://ondinebiopharma.com
Abgenix, Inc.(recently acquired by AMGEN)
De�elopingandmanufacturinghumantherapeuticantibodiesforthetreatmentofcolorectalcancer.
www.amgen.com
Farabloc Development Corp. De�elopedandmanufacturingapainmanagementsolutionforamputeerelatedphantompain
www.farabloc.com
InnerVision Medical Technologies De�elopmentandcommercializationofanultrahighresolution,instant-capture,acousticbasedimagingsystem
www.innermed.com
Millennium Technology Inc. (MTI) De�elopment,manufactureandsaleofMagneticResonanceImaging(MRI)systemstotheglobalhealthcarecommunity.
www.millennium.ca
Chromos Molecular Systems, Inc. De�elopingprogramsfocusedoninflammatorydiseasesandthromboticdisorders
www.chromos.com
�2
British Columbia Technology Sector Profile
Centres for Research and Innovation
4
TheLifeSciencesSectorinB.C.ishometoanumberofworldleadingresearchfacilities.Thephysicalinfrastructureismadeupofresearchfacilitiesatouruni�ersities,researchlabs,fundingagencies,hospitalsandothersupportfacilities.AsampleofB.C.’sinfrastructureisbelow.
Sector Infrastructure BC Centre for Disease Control(BCDC)
www.bccdc.org/ TheBCCDCincludesstateoftheartcontainmentle�el3facilitiesandmoleculardiagnosticcapabilities,aswellascentralizedinformationmanagementsystems.
Michael Smith Genome Sciences Centre (BC Cancer Agency)
www.bcgsc.ca/ Thefirsthigh-throughputgenesequencingcentreinCanadathatisdedicatedtocancerresearch.
Trev & Joyce Deeley Research Centre (BC Cancer Agency)
www.bccrc.ca/drc/index.html
Studiestheimmunesystem’sresponsetocancerandhoststheTumorTissueRepositorywhichpro�idespatientspecimensforbasicandclinicalstudies.
Terry Fox Laboratory (BC Cancer Agency)
www.bccrc.ca/tfl/ Multidisciplinaryresearchincancerdiagnosisandtreatment.
Biomedical Research Centre (UBC)
www.brc.ubc.ca/brc/
Conductsmulti-disciplinaryresearchonthebody’sprocessestodefendagainstmicrobesandcancer,aswellasprocessestorepairtissues.FacilitiesincludetheUBCMulti-userFlowCytometry(FACS)Facility,UBCTransgenicFacility,andtheCollaborati�eFacilityforProteomics.
Center for Drug Research and Development
www.cdrd.ca
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
�3
Michael Smith Biotechnology Labs (UBC)
www.michaelsmith.ubc.ca/
Canada’sfirstinterdisciplinarybiotechnologyunit,foundedin�987,whichfocusesonhuman/animalmoleculargenetics,fermentationandbio-processengineering,plantandforestrymoleculargeneticsandbioinformatics.
Brain Research Centre (UBC)
www.brain.ubc.ca/
Anindependentresearchfacilitywitho�er�75in�estigatorsengagedinmulti-disciplinaryneuroscienceresearch.CorefacilitiesincludethePeptideArrayFacilityandtheLenti�irusFacility.
James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research (UBC)
www.icapture.ubc.ca/home.shtml
LocatedatSt.Paul’sHospital,theiCAPTURECentrehasfourcoreareas;molecularphenotyping,ultrastructuralimaging,dynamiccellularimagingandbiophysics,andorganpathophysiologyandimaging.TheCentreusesad�ancedcomputingtoidentifylinksbetweengeneticinformation,clinicaldataandphenotypicdata.
Centre for Molecular Medicine and Therapeutics (CMMT) UBC
www.cmmt.ubc.ca/
Conductsresearchonthedeterminationandcontrolofgeneticsusceptibilitytodisease.TheCMMThascorefacilitiesinthefollowingareas:bioinformatics,transgenics,genotyping,BioAnalyzer,andDNAsequencing.
Canadian Bioinformatics Resource (BCIT)
www.bcit.ca/appliedresearch/gait/projects/cbri.shtml
Canada’sfirstdedicatedindustry-orientedbioinformaticstrainingfacility,jointlyestablishedbytheNationalResearchCouncil,BCIT,andVitesseCanada.
Bioinformatics at Simon Fraser University (SFU)
www.bioinformatics.sfu.ca/
Offeringtrainingandresearchinbioinformatics,facultyincludes,Dr.Da�idBaillie,aCRCChairinGenomicsintheDepartmentofMolecularBiologyandBiochemistry(MBB),andDr.FionaBrinkman,listedbyMITTechnologyRe�iewsasoneoftheworlds“topyounginno�ators”,andin�ol�edinanumberofmicrobialpathogenbioinformaticsprojects.
University of Victoria Genome BC Proteomics Centre
www.proteincentre.com/
TheUni�ersityofVictoriaProteomicsCentrehasbeeninoperationsince200�andissupportedbycollaborati�erelationshipswithGenomeBCandGenomePrairie.Baseduponacostreco�eryfinancingmodel,theProteomicsCentrepro�idesanarrayofcomputer-basedanalyticalser�ices.
�4
British Columbia Technology Sector Profile
Skilled Workforce
5
Thenumberofgraduatestudentsisoftenconsideredindicati�eoftheskillle�elanddepthofknowledgeandexperienceinaregion.ThefollowingtableillustratesthenumberofgraduatestudentsenrolledinscienceprogramsinB.C.uni�ersitiesfrom200�-2002to2005-2006.Inaddition,thissectionpro�idesinformationonsomeofB.C.’sresearchacti�ities.
�5
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
Number of Graduate Students Enrolled in British Columbia Universities
Graduate Students 2005/06 2004/05 2003/04 2002/03 2001/02
MasterofEngineering �29 �43 �66 �95 �77
MasterofAppliedScience 586 632 609 575 506
MasterofScience 2,080 2,074 �,894 �,894 �,794
MasterofHealthScience 28 32 28 3� 35
MasterofHealthAdministration 56 63 67 56 47
MasterofScience/DiplomainPeriodontics 7 9 �0 �0 8
BachelorofAppliedScience/MasterofEngineering 9 8 6 7 �0
Source: The University Presidents’ Council of British Columbia (TUPC). Data are as of September 2006.
Number of Undergraduate Students Enrolled in British Columbia Universities
Undergraduate Students 2005/06 2004/05 2003/04 2002/03 2001/02
BachelorofAppliedScience 3,883 3,623 3,387 3,062 2,8�3
BachelorofEngineering 764 770 777 73� 720
BachelorofMedicalLaboratoryScience 33 25 25 �3 �8
BachelorofScience �6,0�8 �5,58� �5,382 �4,4992 �4,7�4
BachelorofScience(TechBC) - 726 542 233 -
Source: The University Presidents’ Council of British Columbia (TUPC). Data are as of September 2006.
�6
British Columbia Technology Sector Profile
Research Chairs CanadaResearchChairsmaybeeitherTier�orTier2.Tier�Chairsareawardedtooutstandingresearchersrecognizedbytheirpeersasworldleadersintheirrespecti�eresearcharea.Thesechairsarerenewable,andtheresearcher’suni�ersityrecei�es$200,000annuallyforse�enyears.Tier2Chairsareawardedtoemergingresearchersrecognizedbytheirpeersaspotentialworldleadersintheirareaofresearch.Tier2Chairsarerenewableonce,andtheresearcher’suni�ersityrecei�es$�00,000annuallyforfi�eyears.
Research Strengths – Number of Research Chairs
Canada Research Chairs in Life SciencesTier� 25Tier2 34NSERCResearchChairs 3LeadingEdgeEndowmentFundChairs 4LeadingEdgeEndowmentFund-In�itedProposals 5
Thefollowingliststhetitlesoftheresearchchairsidentifiedintheabo�etable.
5
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
�7
Titles Canada Research Chairs
Research Chair Title Year Awarded
Research Chair Department School
Tier� Biodi�ersityandSystematicsMay�,2003
WayneP.Maddison ZoologyandBotany UBC
BiotechnologyandGenomics-NeurobiologyJune�,2005
TerranceP.Snutch Psychiatry,Zoology UBC
BrainDe�elopmentNo�ember�,200�
MaxS.Cynader OphthalmologyandVisualSciences
BrainResearchCentre
CNSDisordersJanuary�,200�
A.JonStoessl Medicine UBC
GapJunctionsandDiseaseMarch�,2003
ChristianC.GNaus CellularandPhysiologicalSciences
UBC
GenomicsandMolecularBiologyJanuary�,2004
BenF.Koop Biology UVIC
Genomics/InformaticsNo�ember�,200�
Da�idL.Baillie MolecularBiologyandBiochemistry
SFU
HumanGeneticsandMolecularMedicineJanuary�,200�
MichaelR.Hayden MedicalGenetics
ImmunologyJanuary�,200�
JohnSchrader Medicine,MicrobiologyandImmunology,PathologyandLaboratoryMedicine
UBC
Integrati�eAnimalPhysiologyJuly�,2005
RobertShadwick Zoology UBC
IntelligentComputerInterfaceDesignJanuary�,200�
SeptimiuE.Salcudean
ElectricalandComputerEngineering
UBC
�8
British Columbia Technology Sector Profile5MaterialsSciencesAugust�,2006
NeilBranda Chemistry SFU
MetalloproteinaseProteomicsandSystemsBiologyJanuary�,200�
ChristopherM.O�erall
OralBiologyandMedicalSciences
UBC
MolecularCardiacPhysiologyOctober�,2003
GlenTibbits Kinesiology SFU
MolecularImmunityMay�,2004
JamieK.Scott MolecularBiologyandBiochemistry
SFU
NeurobiologyJuly�,2004
AnnMarieCraig Psychiatry UBC
NeurodegenerationandProteinMisfoldingDiseaseJanuary�,2004
NeilCashman MedicineandVancou�erCoastalHealth
UBC
NeuroscienceJuly�,2003
BrianA.MacVicar Psychiatry UBC
PathogenomicsandAntimicrobialsJanuary�,200�
RobertE.WHancock MicrobiologyandImmunology
UBC
ProteasesandDiseaseOctober�,2003
DieterBromme Biochemistry UBC
Reproducti�eHealthJuly�,2004
GeoffreyHammond ObstetricsandGynaecology UBC
SurfaceBiotechnologyJuly�,200�
CharlesHaynes ChemicalandBiologicalEngineering
UBC
SyntheticOrganicChemistryOctober�,2004
MarcoCiufolini Chemistry UBC
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
�9
TransfusionScienceJuly�,200�
A.GrantMauk Biochemistry UBC
VisualScienceJanuary�,200�
RobertS.Molday OphthalmologyandVisualSciences,Biochemistry
UBC
Tier2 AirwayDiseaseJuly�,2004
DarrylKnight PharmacologyandTherapeutics
UBC
Alzheimer’sDiseaseJune�,2002
WeihongSong Psychiatry UBC
BacterialPathogenesisJune�,2003
ErinGaynor MicrobiologyandImmunology
UBC
BiologyofParasitesandDiseaseVectorsApril�,2002
CarlA.Lowenberger SFU
BiomaterialsJanuary�,2002
RizhiWang MetalsandMaterialEngineering
UBC
Cardio�ascularBiochemistryMay�,2003
Da�idJ.Gran�ille PathologyandLaboratoryMedicine
UBC
CellTherapiesSeptember�,2002
ClaytonA.Smith Medicine UBC
ChemicalGlycobiologyMarch�,2004
Da�idJ.E.Vocadlo Chemistry SFU
ChronicObstructi�ePulmonaryDiseaseJuly�,2004
DonD.Sin Medicine UBC
ComputationalGenomicsOctober�,2003
S.CenkSahinalp ComputingScience SFU
DrugDisco�eryOctober�,2005
AdamFrankel PharmaceuticalSciences UBC
20
British Columbia Technology Sector Profile
Enology/YeastGenomicsOctober�,2003
Vi�ienMeasday FacultyofLandandFoodSystems
UBC
GeneticSusceptibilitytoInflammatoryAirwayDiseasesJuly�,200�
AndrewJ.Sandford Medicine UBC
GeneticsandBeha�iourJanuary�,200�renewedNo�ember�,2005
ElizabethM.Simpson MedicalGenetics UBC
GenomicImprintingJanuary�,2003
LouiseLefeb�re Ci�ilEngineering UBC
InjuryPre�entionandMobilityBiomechanicsApril�,2005
StephenRobino�itch Kinesiology SFU
MaterialsandStructuralBiologySeptember�,2003
EldonEmberly Physics SFU
MEMSandNanotechnologyforBiomedicalDe�icesApril�,2004
MuChiao MechanicalEngineering UBC
MolecularInteractionJanuary�,2003
AlisdairB.Boraston BiochemistryandMicrobiology
UVIC
MolecularNanoscienceandProteinEngineeringOctober�5,2004
HongbinLi Chemistry UBC
MolecularOncologyJanuary�,2005
SamuelAparicio PathologyandLaboratoryMedicine
UBC,BCCancerResearchcenter
MolecularPathogenesisJuly�,2006
CarolineCameron BiochemistryandMolecularBiology
UVIC
NaturalProductsChemistryOctober�,2005
SusanMurch Chemistry,EarthandEn�ironmentalSciences
UBC(Okanagan)
5
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
2�
NeuropharmacologyJuly�,2003
BrianCairns PharmaceuticalSciences UBC
NeuropsychologyofVisionandEyeMo�ementsSeptember�,2004
JasonBarton OphthalmologyandVisualSciences
UBC
OrganellarProteomicsOctober�,2005
LeonardFoster Biochemistry UBC
PacemakerChannelBiologyAugust�,2005
EricAccili CellularandPhysiologicalSciences
UBC
PediatricGastroenterologyJuly�,2004
BruceA.Vallance Pediatrics UBC
ProkaryoticMembraneBiologyMarch�,2004
FranckDuong Biochemistry UBC
Regenerati�eMedicineJuly�,200�
FabioRossi MedicalGeneticsSenior UBC
RetinalandEarlyEyeDe�elopmentMarch�,2005
RobertL.Chow Biology UVIC
SpinalCordBiomechanicsJuly�,200�
ThomasR.Oxland MechanicalEngineering UBC
TheoreticalBiophysicsNo�ember�,200�
Ste�enS.Plotkin PhysicsandAstronomy UBC
TransplantationJuly�,2003
MeganK.Le�ings Surgery UBC
NSERCResearchChairs
En�ironmentalContaminants,FoodSecurityandIndigenousPeoplesoftheNorthGrantrecei�edbetween2002and2005
LaurieHingManChan
CommunityHealth Uni�ersityofNorthBritishColumbia
22
British Columbia Technology Sector Profile
PhotodynamicTechnologiesGrantrecei�edbetween�99�-2005
Da�idDolphin Chemistry UBC
ScientificInstrumentationGrantrecei�edbetween�995-2005
DonaldDouglas Chemistry UBC
LeadingEdgeEndowmentFundChairs
Dr.DonaldB.RixLeadershipChairinAboriginalEn�ironmentalHealthFebruary2006
LaurieHingManChan
CommunityHealth Uni�ersityofNorthBritishColumbia
DepressionResearchNo�ember2005
AllanYoung Psychiatry UBC
ProstateCancerResearchJuly2005
MartinGlea�e Surgery UBC
SpinalCordInjuryResearch2002
JohnStee�es Zoology,AnatomyandSurgery
UBC
5
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
23
TechnologyPartnershipsCanada(TPC)isaSpecialOperatingAgencyofIndustryCanadathatmakesstrategicin�estmentstosupportresearch,de�elopmentandinno�ation.Thesein�estmentsareintendedtoencouragepri�atesectorin�estmentsinresearchandde�elopment.
IntheLifeSciencessector,TPChasappro�edonecontributionof$9.8millionwhichwasawardedtoMIGENIXInc.in2004-2005.
Technology Partnerships Canada – R&D Projects (2004-2005)
Company MIGENIX Inc
Project Antibioticdrugthatmaybeeffecti�e(asshowninpreclinicaltrials)intreatinghospital-acquiredinfections
Appro�edcontribution $9.8million
TheNRCIndustrialResearchAssistanceProgram(NRC-IRAP)pro�idesarangeoftechnicalandbusinessorientedad�isoryser�icesalongwithpotentialfinancialsupporttogrowth-orientedsmall-andmedium-sizedbusinessesandhasbeenasignificantcontributorinsupportingthecommercializationoflifescienceresearch.Theprogramreliesonanextensi�enetworkofprofessionalsacrossthecountryworkingdirectlywithclientssupportinginno�ati�eresearchandthede�elopmentandcommercializationofnewproducts.In2004/05,NRC-IRAP’snearly$�30millionintotalexpendituresaidedinbuildingtheinno�ati�ecapacitiesofo�er�0,000firmswithdirectfinancialsupportdistributedacrosso�er2,500projects.
24
British Columbia Technology Sector Profile
0
26000
52000
78000
104000
130000
2006
$62,780
2005
$121,600
2004
$91,040
2003
$67,350
5
10
15
20
Total#ofDeals 7 13 9 17
VC Investment(000s)
Equity Investment in VC Backed Companies - B.C. Life Sciences SectorThedataisbasedon�enturecapitalin�estmentsinB.C.basedLifeSciencescompaniesandallamountsarereportedinCanadiandollars.ThisdataistakenfromtheVCReporterdatabasefromThomsonFinancial.Sometransactionsmayha�eoccurredthatha�enotbeencapturedintheThomsonFinancialdatabaseormayberecordedinU.S.datasourcesiftheacquisitionwasbyaU.S.-basedfirm.
Fiscal IncentivesThefollowingtablespro�ideprograminformationforfiscalincenti�esa�ailabletoeligiblecompaniescarryingonbusinessorresidentslocatedinB.C.Alloftheincenti�eslistedaretaxcreditsa�ailablefromeitherthepro�incialorfederalgo�ernments.
Finance and Capitalization
6
* Actual VC investment is higher as the amount of some deals not known.
25
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
Research and Development Investment Tax CreditsCanadaandBritishColumbiaofferagenerousprogramofresearchandde�elopmenttaxcreditstosupportinno�ation.ThesecreditscanbeusedtosubstantiallyfundR&Dandare�eryattracti�etocompaniesestablishingthemsel�esinthepro�ince.
TheScientificResearch&ExperimentalDe�elopment(SR&ED)isthefederalprogramdesignedtoencouragebusinesses,includingsmallandstart-upcompanies,todoworkthatad�ancestechnologytode�elopneworimpro�edproductsorprocesses.
SR&EDpro�idescompanieswitheitherrefundableornonrefundabletaxcreditsforeligibleexpendituresincurredinCanadaforresearchandde�elopmentacti�ities.CompaniesqualifyingasaCCPC(CanadianControlledPri�ateCorporation)areeligibletorecei�ea35percentin�estmenttaxcreditonupto$2millionofqualifiedexpendituresand20%ofqualifiedexpendituresnoteligibleforthe35percentrate.NonCCPC’sareonlyeligibletorecei�etaxcreditsof20percentofqualifiedexpenditures.Allcompaniesareabletocarryforwardfederalin�estmenttaxcreditsfor20years(from2006).
Canada – Federal Scientific Research and Experimental Development (SR&ED) Policy Detailsiv
Tax Credit Qualifying Entities Tax Credit Rate Refund Rate Further Detailsv Who Qualifies?
ScientificResearch&ExperimentalDe�elopmentTaxCreditProgram(SR&ED)
QualifyingCanadianControlledPri�ateCorps.(CCPCs)
35 %ofannualexpendituresuptothresholdof$2million
+20 %ofqualifiedexpendituresnoteligibleforthe35%rate.
100 %ofITCsoncurrentexpenditurecomputedatthe35%rate
+40 %ofITCsoncapitalexpenditurescomputedatthe35%rateandofITCsofaqualifyingcorporationatthe20%rate.
TheSR&EDisarefundabletaxcredit,whichmeansthate�enifaneligiblefirmisnotprofitable,itwillstillgetacashrefundfromengaginginR&D.
Fornon-CCPCs,e�enthoughnorefundisa�ailable,theprogramallowsfirmstoreducetaxespayableforanetpositi�ecashflow.
Qualifiedresearchmustfitad�ancement,uncertaintyandcontentcriteria.
NonCCPC’s 20% N/A
Indi�iduals 20% 40%ofITCs
26
British Columbia Technology Sector Profile
UndertheB.C.pro�incialin�estmenttaxcreditprogram,eligiblecorporationscantakea�0percenttaxcreditagainstpro�incialincometaxinadditiontorecei�ingfederalSR&EDtaxcredits.SimilartotheSR&EDprogram,CCPC’sareeligibleforrefundswhilenon-CCPC’smustapplythecreditagainsttaxespayable.
Province of British Columbia British Columbia R&D Tax Credit Policy Detailsvi
Tax Credit Qualifying Entities Tax Credit Rate Refund Rate Further Detailsv Who Qualifies?
BritishColumbiaPro�incialR&DTaxCredit
QualifyingCanadianControlledPri�ateCorps.(CCPCs)
�0percentCreditAgainstPro�incialIncomeTax
Refundable QualifyingCCPCsarerefundableonthefirst$2millionofexpenditureseligibleforSR&EDcredit.
Qualifiedresearchmustfitad�ancement,uncertainty,andcontentcriteria.
OtherCorporations Non-refundableOtherCorporationsmaycarrythetaxcreditforward�0yearsandback3years.
International Financial Activity (IFA) Act vii
B.C.’sInternational Financial Activity (IFA) ActcameintoeffectonSeptember�,2004,andpro�ideseligiblecorporationsandspecialistswitharefundonB.C.incometaxpaidonincomethatisrelatedtothecorporation’sinternationalfinancialacti�itiesconductedinB.C.TheIFA Actwasestablishedtosupportcertainbusinessacti�itiesbyessentiallyexemptingincomefromtheseacti�itiesfrompro�incialincometaxorpro�idingasignificantreductionintheeffecti�epro�incialtaxrate.
Theseacti�ities,allofwhichmustbecarriedonwithanon-residentperson,includes:makingloans,financingforeignaffiliates,factoringtradeaccountsrecei�ables,distributionoffilmandtele�isionrights,leasingproperty,capti�einsuranceacti�itiesandforeignexchangeacti�ities.Acorporationmayrecei�eanannualrefundof�00percentofthepro�incialincometaxpaidonincomeearnedfromtheseacti�ities.AnIFAspecialistiseligibletorecei�earefundofupto75percentofincometaxespaid.
Effecti�eJanuary�,2006,theIFAhasbeenexpandedtoincludetherefundofincometaxpaidonincomederi�edfromcertaintypesoflifesciencespatents�iii.Corporationsmayrecei�eanannualtaxrefunduptothelesserof$8millionand75percentofitscorporateincometaxpaidonincomethatisderi�edfrominternationalcommercializationoflifesciencespatents.
6
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
27
Tobeeligiblefortherefund,patentsmustha�eaprimaryclassificationnumberinaccordancewiththeInternationalPatentClassificationandnotha�eexpired.Broadclassificationsforthetypesofpatentsthatqualifyforrefundsincludethefollowing:newplantorprocessesforobtainingthem,preser�ationofbodiesofhumansoranimal,biochemistry,microbiology,in�estigationoranalyzingfood,andin�estigationoranalyzingbiologicalmaterial.Thisprogramissummarizedinthefollowingtable.
Province of British Columbia International Financial Activity (IFA) Policy Detailsix
Tax Credit Qualifying Entities Refund Rate Further Details Who Qualifies?
BritishColumbiaInternational Financial Activity Act
IncorporatedCanadiancompanieswithpermanentestablishmentsinB.C.
�00percentofpro�incialincometaxpaidonnon-lifesciencepatentacti�ity.
Lesserof$8millionand75percentofpro�incialincometaxpaidonlifesciencespatentacti�ity.
Registeredcorporationsmayclaimataxrefundonpatentacti�ityorothereligibleacti�ities(butnotboth)
MustmaintainmembershipinInternationalFinancialCentreBritishColumbiaSociety
Small Business Venture Capital Act (SBVCA)TheB.C.MinistryofEconomicDe�elopmentofferstaxcreditstoresidentin�estorstohelpsmallbusinessescarryingonprescribedacti�itiesgainaccesstoearlystageor‘seed’capitalthrough�enturecapitalprogramsoperatedundertheSmall Business Venture Capital Act (SBVCA).Prescribedacti�itiesincludemanufacturingandprocessingofgoodsinBritishColumbia,researchandde�elopmentofproprietarytechnologies,de�elopmentandoperationofadestinationtouristresortandthede�elopmentofinteracti�edigitalmediaproducts.
Theannualcapforequitycapitalin�estmentunderthisprogramis$83millionofwhich$�0millionofprogramcapitalisreser�edforin�estmentinsmallbusinessesoperatingoutsideoftheLowerMainlandand$�7millionisreser�edforin�estmentinsmallbusinessessubstantiallyengagedinthe‘newmedia’sector.
UndertheSBVCA,programin�estmentismadeeitherthroughaholdingcorporationknownasaVentureCapitalCorporation(VCC)ordirectlytoanEligibleBusinessCorporation(EBC).TheEBCTaxCreditencouragesdirectin�estmentbyin�estorsineligiblesmallbusinessesthroughoutthepro�ince.ProfessionalmanagementoftheVCCfundselectsandmanagesadi�erseportfolioofin�estmentsonbehalfofthepoolofin�estors.DetailsoftheSBVCAprogramareoutlinedinthefollowingtable.
28
British Columbia Technology Sector Profile
Province of British Columbia Small Business Venture Capital Act Policy Details
Tax Credit Qualifying Entities Tax Credit Rate Further Details Who Qualifies?
Small Business Venture Capital Act (SBVCA)
Residentin�estorswhopro�idein�estmentcapitalintoaVCCorEBC
30percentrefundabletaxcreditxforindi�idualstoamaximumof$60,000annually.(Notrefundableforcorporationswithnomaximumlimit.)
Taxcreditisappliedfirstagainstpro�incialandfederaltaxespayable,ifany.
In�estorsmaypro�ideupto$83millionperyearinequitycapitalforin�estmentsinsmallbusiness.
Fortaxcertificatesgreaterthan$60,000,theexcesscanbecarriedforwarduptofouryears
ResidentsandcorporationswithB.C.taxespayable
TheVentureCapitalCorporation(VCC)TaxCreditencouragesin�estmentinsmallbusinessesoperatingoutsideoftheGreaterVancou�erandCapitalRegionalDistricts.
Employee Investment Act TheLabour-SponsoredEmployee Investment Actpro�idesin�estorswiththeopportunitytorecei�eapro�incialtaxcreditof�5percentandafederaltaxcreditof�5percentontheirin�estmentinthefund.Thefundsseeklong-termequityin�estmentopportunitiesincompaniesseeking‘expansion’capital.
Labour-SponsoredFundsareregisteredundertheEmployee Investment Actandareownedbyshareholderswhorelyonprofessionalmanagementtoselectin�estments.TwoLabour-SponsoredFundsthatareregisteredinthepro�inceincludeAlturaGrowthFund(EVCC)Inc.andtheWorkingOpportunityFund(EVCC)Ltd.
Social Service Tax ActTheB.C.SocialSer�iceTaxisapro�incialsalestaxof7percentle�iedonthepurchasepriceoftangiblepersonalproperty.Eligiblemanufacturerspurchasingproductionequipmentandmachinerycanapplyforanexemptionofthesalestaxxi.
6
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
29
Province of British Columbia B.C. Sales Tax Exemption for Equipment and Machinery Policy Detailsxii
Tax Credit Qualifying Entities Tax Exemption Rate Further Details Who Qualifies?
Social Service Tax Act
Manufacturers Exemptfrom7percentPST Productionmachineryandequipmentpurchasedorleasedbymanufacturersareexemptfromtax
Mustmeetdefinitionofmanufacturerandequipmentmustbeusedprimarilyanddirectlyinmanufactureofqualifyingtangiblepersonalproperty
30
British Columbia Technology Sector Profile
Thefollowingtwodiagramsillustratethe�aluechain/ecosystemsfortwoLifeSciencessub-sectorsinB.C.;biopharmaceuticalsandmedicalde�ices.Organizationsthatsupportorpro�ideser�icestothesectorareplacedintothetopandmiddleofthediagramaccordingtotheirfunctionasfollows:
Industrysupportorganization,Infrastructure,Researchfacility,Specializedfinancialorganization,orEducationandhumanresourcessupportorganization.
•••••
Value Chain / Ecosystem
7
Life Sciences Sector: Opportunities for Investment, Talent and Enterprise
3�
Biopharmaceuticalisrepresentedinthefirst�aluechain/ecosystemdiagramthatincludesacti�itiessuchas:
Targetidentification,Drugdisco�ery,Clinicaltrials,andProductionandmanufacturing.
MedicalDe�icesareshowinthesecond�aluechain/ecosystemdiagramthatincludestheseacti�ities:
Designandde�elopment,Productionandmanufacturing,Commercializationser�ices,Supplyanddistribution,andGlobalmarketing.
••••
•••••
32
CANREG PRA InternationalRocket BuildersBioPharma Solutions
••••
Strategic Consulting Regulatory and Compliance Support
Active Pass Pharmaceuticals Allon TherapeuticsAmgenAngiotech Pharmaceuticals AnorMED IncARC PharmaceuticalsCardiome PharmaceuticalsCelator TechnologiesChemokine TherapeuticsChromos Molecular SystemsClera IncenGeneForbes Medi-tech
•••••••••••••
GeneMax iCell TherapeuticsiCo TherapeuticsInex PharmaceuticalsInimex PharmaceuticalsInflazyme PharmaceuticalsMed BioGene IncMigenix IncNetwork ImmunologyNeuromed PharmaceuticalsNovation PharmaceuticalsNventa BiopharmaceuticalsOncogenex
•••••••••••••
BRI Pharmaceutical ResearchVancouver Coastal Health Research InstituteBiofine InternationalEmergentec Business AnalyticsSyreon Corp
••
•••
Drug DiscoveryTarget Identification
Contract ManufacturingCANREGPharmEng Technology
••
PRA International• Immuno-Precise AntibodiesPepMetric TechnologiesNorthern Lipids
•••
Biopharmaceuticals Value Chain / Ecosystem
Pre-Clinical ServicesContract Research Organizations
Aska ResearchAvan BiotechAurora BiomedicalBRI Pharmaceutical ResearchCantestI.G Micromed EnvironmentalPRA InternationalPrime TrialsSyreon CorpVancouver Coastal Health Research InstituteWax-it Histology Services
•••••••••••
Clinical Services
Ondine BiopharmaPacgen BiopharmaceuticalsPanagin PharmaceuticalsPrescient NeuropharmaProtiva BiotherapeuticsProtox TherapeuticsQLT IncSirius GenomicsTwinstrand TherapeuticsWelichem BiotechWex PharmaceuticalsXenon Pharmaceuticals
••••••••••••
Research Organizations
Active Pass Pharmaceuticals Allon TherapeuticsAmgenAngiotech Pharmaceuticals AnorMED IncARC PharmaceuticalsCardiome PharmaceuticalsCelator TechnologiesChemokine TherapeuticsChromos Molecular SystemsClera IncenGeneForbes Medi-tech
•••••••••••••
GeneMax iCell TherapeuticsiCo TherapeuticsInimex PharmaceuticalsInflazyme PharmaceuticalsMed BioGene IncMigenix IncNetwork ImmunologyNeuromed PharmaceuticalsNovation PharmaceuticalsNventa BiopharmaceuticalsOncogenexOndine Biopharma
•••••••••••••
Pacgen BiopharmaceuticalsPanagin PharmaceuticalsPrescient NeuropharmaProtiva BiotherapeuticsProtox TherapeuticsQLT IncSirius GenomicsTekmira TherapeuticsWelichem BiotechWex PharmaceuticalsXenon Pharmaceuticals
•••••••••••
BCIT Health Technology Research GroupUBC University-Industry Liaison Office (UILO)SFU University-Industry Liaison Office (UILO)BC Cancer AgencyBiomedical Research Centre (UBC)Brain Research Centre (UBC)Canadian Genetic Disease NetworkCanadian HIV Trials NetworkCentre for Integrated GenomicsGenome BCiCAPTURE Centre for Cardiovascular and Pulmonary Research
•••••••••••
ICORD (Spinal Cord Research)Michael Smith Foundation for Health ResearchSARS Accelerated Vaccine InitiativeStemcell NetworkInvestigational Drug Program (BC Cancer Agency)UBC Centre for Molecular Medicine and TherapeuticsSimon Fraser UniversityUniversity of VictoriaUniversity of Northern British ColumbiaBCIT
••••••••••
33
Enabling Technologies Lobbying and Industry Support
Production and ManufacturingClinical Trials
Industry Support OrganizationsQuality Assurance
PharmEng Technology• Bioinformatics:Genologics Life Sciences Software Kinexus Bioinformatics
•MedBioGene IncZymeworks
••
Life Sciences BCBC Innovation Council
••
Allon TherapeuticsAngiotech Pharmaceuticals AnorMED IncAspreva PharmaceuticalsCardiome PharmaceuticalsCelator TechnologiesChemokine TherapeuticsDragon Pharmaceuticals IncForbes Medi-techiCo TherapeuticsInex Pharmaceuticals CorpInflazyme PharmaceuticalsMigenix Inc
•••••••••••••
Neuromed PharmaceuticalsOncoGenex TechnologiesPacGen PharmaceuticalsProtiva BiotherapeuticsProtox TherapeuticsQLT IncTwinstrand TherapeuticsUrigen Holdings Wex Pharmaceuticals
•••••••••
QLT Inc•
Industry InfrastructureBC Advantage FundsBC Angel ForumBusiness Development Bank of Canada (BDC)Discovery CapitalGrowthWorksOVP Venture PartnersPenderFund Capital Management SmartSeed Equity IncUniversity Medical Discoveries IncVancouver Angel Technology NetworkVentures West WUTIF Capital
••••••••••••
Specialized Finance Education and HR SupportACTECHCanadian Technology Human Resource BoardBioTalent CanadaSimon Fraser UniversityUniversity of VictoriaUniversity of Northern British ColumbiaUniversity of British ColumbiaBCIT
••••••••
Discovery ParksUBC University-Industry Liaison Office (UILO)SFU University-Industry Liaison Office (UILO)Vancouver Island Technology Park
••••
34
BIoLytical LaboratoriesClinotech Diagnostics and PharmaceuticalsCoolhead Technologies IncEaglePicher Medical PowerFarabloc Development CorpMcKesson Medical ImagingMillenium Technology IncMIV Therapeutics
••
••••••
Perceptronix Medical IncProgressive Health InnovationsPyng Medical Corp QDevice Medical IncSaturn Biomedical Systems IncSorin Group Canada, Mitroflow DivisionTexon TechnologiesVSM MedTech LtdXillix Technologies Corp
••••••
•••
Angiometrix IncClinotech Diagnostics and PharmaceuticalsCoolhead Technologies Creation TechnologiesDelfi Medical Innovations EaglePicher Medical PowerEIDAM Diagnostics CorporationFarabloc Development Innovatek Medical IncInternational Newtech Development
••
•••••
•••
Production and Manufacturing
Research Facilities Pacific Centre for Advanced Materials and Structures (4D Labs, SFU)BCIT Technology Centre Health Technology Research Group
••
Industry InfrastructureJack Bell Research CentreMedical Device Development Centre (MDDC)Vancouver Island Technology ParkDiscovery ParksUBC University-Industry Liaison Office (UILO)
•••••
Design and Development
Triumph CommunicationsDEQPRO Medtech Solutions
••
Strategic Consulting Regulatory and Compliance Support Contract ManufacturingWisdahl Consulting Group• Starfish Medical
Epic Biosonics IncDatrend Systems Inc
•••
Medical Devices Value Chain / Ecosystem
LifeScan Canada LtdMcKesson Medical ImagingMDMI TechnologiesMedsurge Medical CorpMillenium Technology IncOrtho ActivePerceptronix Medical IncPM DevicesPrimeLine Medical ProductsPyng Medical Corp Response BiomedicalQDevice Medical IncSaturn Biomedical Systems
•••••••••••••
Sorin Group Canada, Mitroflow DivisionTidal PhotonicsUltrasonix Medical CorpUrodynamix TechnologiesVancouver BiotechViagenX BIotechVSM MedTech LtdXillix Technologies Corp
•••••••••
SFU University-Industry Liaison Office (UILO)BC Medical Device Development Technologies Association (BC MedTech)BC BioProducts Association
••
•
35
Bowers Medical Supply Co• Tokyo Medical Services Co Ltd.•
Supply and Distribution Global Marketing
Specialized Finance BC Advantage FundsBC Angel ForumBC Discovery FundDiscovery CapitalGrowthWorksUniversity Medical Discoveries IncVancouver Angel Technology Network
•••••••
Education and HR SupportCanadian Technology Human Resource BoardBiotechnology Human Resource Council
••
Urodynamix TechnologiesMedical Ventures Corp
••
Commercialization Services
Research Facilities Pacific Centre for Advanced Materials and Structures (4D Labs, SFU)BCIT Technology Centre Health Technology Research Group
••
Contract Design and Prototyping Lobbying and Industry Support
Industry Support Organizations
Quality AssuranceBSI Management Systems Canada IncWisdahl Consulting Group
••
Form3 Design IncJdi Design IncBalbo Medical Systems
•••
Epic Biosonics IncDatrend Systems Inc
••
Life Sciences BCBC MedtechBC Innovation Council
•••
36
British Columbia Technology Sector Profile
Endnotes
i Biotechnology can be defined as “the application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services” (OECD, 2005).
ii University of British Columbia Public Affairs
iii Companies included as the twenty largest companies ranked the highest by 2005 revenue according to Business in Vancouver Magazine’s, Hightech British Columbia 2006, issue and by 2004 revenue according to Business in Vancouver’s, Book of Lists 2005. Annual revenues were also confirmed by reviewing the most recent annual report for each company. In cases where the annual revenue figures differed between these sources, revenues from the company’s annual report were used. The Business in Vancouver publications were also used as sources of information on employment numbers. Finally, Factiva was used to supplement revenue and employment data where that data was unavailable. Where revenues are reported in US$, they have been converted to CA$ based on the monthly average CA$/US$ exchange rate of the last month of the company’s fiscal year. Where revenues are not from a company’s annual report, the annual 2005 exchange rate is used to convert the revenues to CA$.
iv PricewaterhouseCoopers, Tax Facts and Figures for Individuals and Corporations, 2006
v Susan Ward. Don’t Miss Out on the SR&ED Tax Credit Program. From “Your Guide to Small Business Canada” available at http://sbinfocanada.about.com/od/taxinfo/a/SREDtaxcredit.htm
vi PricewaterhouseCoopers, Tax Facts and Figures for Individuals and Corporations, 2006
vii Ministry of Small Business and Revenue, Bulletin IFA 001, International Financial Activity Overview, Revised February 2006
viii Ministry of Small Business and Revenue, Bulletin IFA 002, Life Science Patents, Revised April 2006
ix PricewaterhouseCoopers Tax Facts and Figures for Individuals and Corporations, 2006
x To the extent credit is made available by the Ministry of Economic Development.
xi Ministry of Small Business and Revenue, Bulletin SST 054, Manufacturers, Revised February 2003
xii PricewaterhouseCoopers, Tax Facts and Figures for Individuals and Corporations, 2006